XML 27 R12.htm IDEA: XBRL DOCUMENT
v3.23.1

Long-Term Investments | 3 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2023 | Dec. 31, 2022
Long Term Investment Abstract |  |
LONG-TERM INVESTMENTS | 5. LONG-TERM INVESTMENTS
| (1) | The ownership percentages of each investee are listed as follows:
|  | Ownership percentage |  |  |
|  | March 31, |  |  | December 31, |  |  | Accounting
Name of related party |  | 2023 |  |  | 2022 |  |  | treatments
Braingenesis Biotechnology Co., Ltd. |  |  | 0.22 | % |  |  | 0.22 | % |  | Cost Method
Genepharm Biotech Corporation |  |  | 0.92 | % |  |  | 0.92 | % |  | Cost Method
BioHopeKing Corporation |  |  | 8.03 | % |  |  | 8.03 | % |  | Cost Method
BioFirst Corporation |  |  | 21.77 | % |  |  | 21.77 | % |  | Equity Method
Rgene Corporation |  |  | 28.85 | % |  |  | 28.85 | % |  | Equity Method
| (2) | The extent the investee relies on the company for its business are summarized as follows:
Name of related party |  | The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd. |  | No specific business relationship
Genepharm Biotech Corporation |  | No specific business relationship
BioHopeKing Corporation |  | Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation |  | Loaned from investee and provides research and development support service
Rgene Corporation |  | Collaborating with the Company to develop and commercialize drugs
| (3) | Long-term investment mainly consists of the following:
|  | March 31, 2023 |  |  | December 31, 2022 |
|  | (Unaudited) |  |  |  |
Non-marketable Cost Method Investments, net |  |  |  |  |  |
Braingenesis Biotechnology Co., Ltd. |  | $ | 7,235 |  |  | $ | 7,169 |
Genepharm Biotech Corporation |  |  | 22,089 |  |  |  | 21,887 |
BioHopeKing Corporation |  |  | 820,519 |  |  |  | 813,014 |
Sub total |  |  | 849,843 |  |  |  | 842,070 |
Equity Method Investments, net |  |  |  |  |  |  |  |
BioFirst Corporation |  |  | - |  |  |  | - |
Rgene Corporation |  |  | - |  |  |  | - |
Total |  | $ | 849,843 |  |  | $ | 842,070 |
| (a) | BioFirst Corporation (the “BioFirst”):
The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of March 31, 2023 and December 31, 2022, the Company owns 21.77% and 21.77% common stock shares of BioFirst, respectively. The Company made prepayment for equity investment in BioFirst to purchase additional 317,000 shares to be issued by BioFirst in the aggregate amount of $623,856 and $618,150, recorded as prepayment for long-term investments as of March 31, 2023 and December 31, 2022, respectively. Summarized financial information for the Company’s equity method investee, BioFirst, is as follows: Balance Sheet
|  | March 31, 2023 |  |  | December 31, 2022 |
|  | (Unaudited) |  |  |  |
Current Assets |  | $ | 1,958,500 |  |  | $ | 1,543,152 |
Non-current Assets |  |  | 801,410 |  |  |  | 739,472 |
Current Liabilities |  |  | 1,675,194 |  |  |  | 2,663,051 |
Non-current Liabilities |  |  | 357,150 |  |  |  | 103,447 |
Stockholders’ Equity (Deficit) |  |  | 727,566 |  |  |  | (483,874 | )
Statement of Operations
|  | Three months Ended March 31, |
|  | 2023 |  |  | 2022 |
|  | (Unaudited) |
Net sales |  | $ | - |  |  | $ | 8,808 |
Gross profit |  |  | - |  |  |  | 6,133 |
Net loss |  |  | (406,233 | ) |  |  | (498,940 | )
Share of losses from investments accounted for using the equity method |  |  | - |  |  |  |  |
(b) | Rgene Corporation (the “Rgene”)
Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and Chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to account for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of March 31, 2023 and December 31, 2022, the Company owns 28.85% and 28.85% Common Stock shares of Rgene, respectively. On March 31, 2023, Dr. Tsung-Shann Jiang has been elected to become the Chairman of Rgene. Summarized financial information for the Company’s equity method investee, Rgene, is as follows: Balance Sheets
|  | March 31, 2023 |  |  | December 31, 2022 |
|  | (Unaudited) |  |  |  |
Current Assets |  | $ | 54,987 |  |  | $ | 68,302 |
Noncurrent Assets |  |  | 288,160 |  |  |  | 303,893 |
Current Liabilities |  |  | 2,491,974 |  |  |  | 2,478,868 |
Noncurrent Liabilities |  |  | 2,048 |  |  |  | 2,441 |
Shareholders’ Deficit |  |  | (2,150,875 | ) |  |  | (2,109,114 | )
Statement of Operations
|  | Three months Ended March 31, |
|  | 2023 |  |  | 2022 |
|  | (Unaudited) |
Net sales |  | $ | - |  |  | $ | - |
Gross Profit |  |  | - |  |  |  | - |
Net loss |  |  | (81,842 | ) |  |  | (149,480 | )
Share of loss from investments accounted for using the equity method |  |  | - |  |  |  | - |
(4) | Disposition of long-term investment
During the three months ended March 31, 2023 and 2022, there is no disposition of long-term investment.
(5) | Losses on Equity Investments
The components of losses on equity investments for each period were as follows:
|  |  | Three months Ended March 31, |
|  |  | 2023 |  |  |  | 2022 |
|  |  | (Unaudited) |
Share of equity method investee losses |  | $ | - |  |  | $ | - |
| 6. LONG-TERM INVESTMENTS
(1) | The ownership percentages of each investee are listed as follows:
|  | Ownership percentage |  |  |
|  | December 31, |  |  | December 31, |  |  | Accounting
Name of related party |  | 2022 |  |  | 2021 |  |  | treatments
Braingenesis Biotechnology Co., Ltd. |  |  | 0.22 | % |  |  | 0.22 | % |  | Cost Method
Genepharm Biotech Corporation |  |  | 0.92 | % |  |  | 0.92 | % |  | Cost Method
BioHopeKing Corporation |  |  | 8.03 | % |  |  | 8.03 | % |  | Cost Method
BioFirst Corporation |  |  | 21.77 | % |  |  | 21.77 | % |  | Equity Method
Rgene Corporation |  |  | 28.85 | % |  |  | 28.85 | % |  | Equity Method
(2) | The extent the investee relies on the company for its business are summarized as follows:
Name of related party |  | The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd. |  | No specific business relationship
Genepharm Biotech Corporation |  | No specific business relationship
BioHopeKing Corporation |  | Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation |  | Loaned from the investee and provides research and development support service
Rgene Corporation |  | Collaborating with the Company to develop and commercialize drugs
(3) | Long-term investment mainly consists of the following:
|  | December 31, 2022 |  |  | December 31, 2021 |
Non-marketable Cost Method Investments, net |  |  |  |  |  |
Braingenesis Biotechnology Co., Ltd. |  | $ | 7,169 |  |  | $ | 7,941 |
Genepharm Biotech Corporation |  |  | 21,887 |  |  |  | 24,244 |
BioHopeKing Corporation |  |  | 813,014 |  |  |  | 900,570 |
Subtotal |  |  | 842,070 |  |  |  | 932,755 |
Equity Method Investments, net |  |  |  |  |  |  |  |
BioFirst Corporation |  |  | - |  |  |  | - |
Rgene Corporation |  |  | - |  |  |  | - |
Total |  | $ | 842,070 |  |  | $ | 932,755 |
(a) | BioFirst Corporation (the “BioFirst”):
The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of December 31, 2022 and 2021, the Company owns 21.77% and 21.77% common stock shares of BioFirst, respectively. During year ended December 31, 2021, the Company made prepayment for equity investment in BioFirst to purchase additional 317,000 shares to be issued by BioFirst in the aggregate amount of $618,150, recorded as prepayment for long-term investments as of December 31, 2022. The amount due from BioFirst has been reclassified as prepayment for investment. Summarized financial information for the Company’s equity method investee, BioFirst, is as follows: Balance Sheet
|  | December 31, 2022 |  |  | December 31, 2021 |
Current Assets |  | $ | 1,543,151 |  |  | $ | 2,205,669 |
Noncurrent Assets |  |  | 739,472 |  |  |  | 959,454 |
Current Liabilities |  |  | 2,663,051 |  |  |  | 2,909,703 |
Noncurrent Liabilities |  |  | 103,447 |  |  |  | 32,522 |
Stockholders’ Equity |  |  | 483,874 |  |  |  | 222,898 |
Statement of operation
|  | Year Ended December 31, |
|  | 2022 |  |  | 2021 |
Net sales |  | $ | 30,162 |  |  | $ | 26,693 |
Gross profit |  |  | 8,239 |  |  |  | 8,348 |
Net loss |  |  | (1,274,539 | ) |  |  | (2,276,892 | )
Share of losses from investments accounted for using the equity method |  |  | - |  |  |  | (269,844 | )
(b) | Rgene Corporation (the “Rgene”)
Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of December 31, 2022 and 2021, the Company owns 28.85% and 28.85% common stock shares of Rgene, respectively. Summarized financial information for the Company’s equity method investee, Rgene, is as follows: Balance Sheets
|  | December 31, 2022 |  |  | December 31, 2021 |
Current Assets |  | $ | 68,302 |  |  | $ | 73,452 |
Noncurrent Assets |  |  | 303,893 |  |  |  | 374,423 |
Current Liabilities |  |  | 2,478,868 |  |  |  | 1,934,786 |
Noncurrent Liabilities |  |  | 2,441 |  |  |  | - |
Shareholders’ Deficit |  |  | (2,481,309 | ) |  |  | (1,486,911 | )
Statement of operations
|  | Year Ended December 31, |
|  | 2022 |  |  | 2021 |
Net sales |  | $ | - |  |  | $ | - |
Gross Profit |  |  | - |  |  |  | - |
Net loss |  |  | (1,550,123 | ) |  |  | (576,514 | )
Share of loss from investments accounted for using the equity method |  |  | - |  |  |  | - |
(4) | Disposition of long-term investment
During the years ended December 31, 2022 and 2021, there is no disposition of long-term investment.
(5) | Losses on Equity Investments
The components of losses on equity investments for each period were as follows:
|  | Year Ended December 31, |
|  | 2022 |  |  | 2021 |
Share of equity method investee losses |  | $ | - |  |  | $ | (269,844 | )

X
- References No definition available. + Details
Name: | abvc_LongTermInvestmentAbstract
Namespace Prefix: | abvc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for long term investment. + References No definition available. + Details
Name: | abvc_LongTermInvestmentTextBlock
Namespace Prefix: | abvc_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration